Flare Capital Partners - Where do Healthcare Budgets Match AI Hype? A 10-Year Lookback of Funding Data - September 2024 logo

Flare Capital Partners - Where do Healthcare Budgets Match AI Hype? A 10-Year Lookback of Funding Data - September 2024

Free

Healthcare AI funding analysis: 10-year lookback on where budgets meet hype

FreeFree tier
Type
Open Source
Company
Flare Capital Partners
LinksX

About Flare Capital Partners - Where do Healthcare Budgets Match AI Hype? A 10-Year Lookback of Funding Data - September 2024

This Medium article by Flare Capital Partners (authors Parth Desai and Jake Rubin) presents a 10-year analysis of healthcare AI venture capital funding, reviewing over 4,000 deals to understand where AI companies have created the most value. It explores the dichotomy between AI's enormous potential in healthcare (estimated at $370 billion) and the relatively low adoption rates (only 6.8% of organizations planning to leverage AI in the next 6 months). The analysis covers how funding spiked in 2013 (deep learning) and 2021–2022 (generative AI), with subsequent plateaus as budgets lag funding hype. It provides sector-specific insights for life sciences, health plans, and health systems, highlighting where AI investments have converted capital to value most efficiently.

Key Features

Analysis of over 4,000 healthcare AI venture capital deals across a decade
Sector-specific breakdowns for life sciences, health plans, and health systems
Insights on AI funding spikes and subsequent plateaus in healthcare
Comparison of AI deal activity relative to overall healthcare venture capital
Metrics on enterprise AI adoption rates across healthcare sectors

Pros & Cons

Pros
  • Data-driven analysis with over 4,000 deals reviewed
  • Covers a full decade of funding trends (2014-2024)
  • Provides sector-specific insights (life sciences, health plans, health systems)
  • Honest about the gap between AI hype and actual enterprise adoption
  • Contextualizes funding spikes relative to major AI technological advances
Cons
  • Limited to funding data only; does not cover AI deployment outcomes or ROI
  • Focuses primarily on US healthcare market
  • Analysis is retrospective and may not predict future trends
  • Does not include specific company examples or case studies

Best For

Healthcare investors assessing where to allocate AI capitalHealth system leaders evaluating AI adoption strategiesHealth plan executives understanding value-based care AI trendsLife sciences companies identifying AI opportunitiesResearchers studying the relationship between AI hype and actual funding